最新临床试验：联合化疗治疗新诊断的高危B型急性淋巴细胞白血病和类ph-tki敏感性突变的年轻患者

这是一项随机的多中心三期临床试验，目的是研究联合化疗在治疗年轻的B型急性淋巴细胞白血病（可能复发或扩散）患者以及费城染色体（ph）样酪氨酸激酶抑制剂（tki）敏感突变患者中的效果。化疗中使用的药物以不同的方式阻止癌细胞的生长，要么杀死癌细胞，阻止癌细胞分裂，要么阻止癌细胞扩散。给予一种以上的药物（联合化疗）和给予不同剂量和不同组合的药物可能杀死更多的癌细胞。

This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.

Primary ID AALL1131
Secondary IDs NCI-2011-03797, NCT01406756, CDR0000706370, COG-AALL1131, S12-01254
Clinicaltrials.gov ID NCT02883049

Status: Active
Age: 1 to 30 years
Gender: Male or Female
Location: 191 locations